(Q28294611)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20885427

24 July 2024

3

S. Ness

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20885427

24 July 2024

author name string

G. Abedi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20885427

24 July 2024

E. Ahmed

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20885427

24 July 2024

M. Fenberg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20885427

24 July 2024

M. K. Daly

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20885427

24 July 2024

A. Houranieh

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20885427

24 July 2024

E. B. Feinberg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20885427

24 July 2024

language of work or name

English

0 references

publication date

November 2010

0 references

1 October 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20885427

full work available at URL

24 July 2024

https://www.nature.com/articles/eye2010147.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20885427

http://www.nature.com/articles/eye2010147.pdf

24 July 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.147

http://www.nature.com/articles/eye2010147

24 July 2024

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.147

24 July 2024

0 references

24

0 references

issue

11

0 references

page(s)

1708-15

0 references

cites work

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Vascular endothelial growth factor in eye disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Vascular endothelial growth factor: biology and therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Increased expression of angiogenic growth factors in age-related maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

Retinal arteriolar narrowing and risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Intravitreal avastin: the low cost alternative to lucentis?

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.147

7 January 2021